Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Last updated: October 10, 2025
Sponsor: Viatris Specialty LLC
Overall Status: Completed

Phase

3

Condition

Acute Pain

Pain

Treatment

Bunionectomy

Placebo

Tramadol

Clinical Study ID

NCT06215820
MR-107A-02-TFZ-3001
  • Ages > 18
  • All Genders

Study Summary

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after bunionectomy.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  1. Requirement for a primary unilateral bunionectomy

  2. Has an American Society of Anesthesiologists Physical Status of I, II, or III.

  3. Pain Intensity (PI) using a Numeric Rating Scale (NRS-R) ≥4 at any given timepointduring the 9 hours after removal of the popliteal sciatic block

  4. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e.,none, mild, moderate, severe) during the 9 hours after removal of the poplitealsciatic block

  5. Able to understand and complete the study requirements (including literacy, toenable diary and questionnaire completion), provide written informed consent, andagree to abide by the study protocol and its restrictions.

Exclusion

Key Exclusion Criteria:

  1. Previously dosed with this formulation of MR-107A-02.

  2. Subjects with a contralateral foot bunionectomy in the past 6 months.

  3. Subject has a concurrent acute or chronic painful physical/restrictive conditionexpected to require analgesic treatment in the postoperative period for pain that isnot strictly related to the bunionectomy, and which may confound the postoperativeassessments.

  4. Known hypersensitivity to aspirin, NSAIDs or other medication used in the study.

  5. Body mass index (BMI) >40 kg/m2 at screening.

  6. Body weight of <43 kg at screening.

  7. History of GI bleeding or peptic ulcer disease.

  8. Known active inflammatory bowel disease, e.g., Crohn's Disease or ulcerativecolitis.

  9. A history of bleeding disorders that may affect coagulation.

  10. Subjects with prior stroke or transient ischemic attack in the past 12 months priorto screening.

Study Design

Total Participants: 410
Treatment Group(s): 4
Primary Treatment: Bunionectomy
Phase: 3
Study Start date:
December 29, 2023
Estimated Completion Date:
September 30, 2024

Connect with a study center

  • Investigator site 114

    Sheffield, Alabama 35660
    United States

    Site Not Available

  • Investigator site 114

    Sheffield 4089536, Alabama 4829764 35660
    United States

    Site Not Available

  • Investigator site 115

    Phoenix, Arizona 85053
    United States

    Site Not Available

  • Investigator site 115

    Phoenix 5308655, Arizona 5551752 85053
    United States

    Site Not Available

  • Investigator site 103

    Anaheim, California 92801
    United States

    Site Not Available

  • Investigator site 110

    Riverside, California 92501
    United States

    Site Not Available

  • Investigator site 103

    Anaheim 5323810, California 5332921 92801
    United States

    Site Not Available

  • Investigator site 110

    Riverside 5387877, California 5332921 92501
    United States

    Site Not Available

  • Investigator site 112

    Miami, Florida 35660
    United States

    Site Not Available

  • Investigator site 108

    Tampa, Florida 33613
    United States

    Site Not Available

  • Investigator site 112

    Miami 4164138, Florida 4155751 35660
    United States

    Site Not Available

  • Investigator site 108

    Tampa 4174757, Florida 4155751 33613
    United States

    Site Not Available

  • Investigator site 109

    Atlanta, Georgia 30331
    United States

    Site Not Available

  • Investigator site 109

    Atlanta 4180439, Georgia 4197000 30331
    United States

    Site Not Available

  • Investigator site 104

    O'Fallon, Illinois 62269
    United States

    Site Not Available

  • Investigator site 104

    O'Fallon 4245926, Illinois 4896861 62269
    United States

    Site Not Available

  • Investigator site 102

    Pasadena, Maryland 21122
    United States

    Site Not Available

  • Investigator site 102

    Pasadena 4364990, Maryland 4361885 21122
    United States

    Site Not Available

  • Investigator site 113

    Bellaire, Texas 77401
    United States

    Site Not Available

  • Investigator site 107

    Carrollton, Texas 75007
    United States

    Site Not Available

  • Investigator site 106

    Houston, Texas 77008
    United States

    Site Not Available

  • Investigator site 111

    McAllen, Texas 78501
    United States

    Site Not Available

  • Investigator site 105

    San Antonio, Texas 62269
    United States

    Site Not Available

  • Investigator site 113

    Bellaire 4673353, Texas 4736286 77401
    United States

    Site Not Available

  • Investigator site 107

    Carrollton 4679195, Texas 4736286 75007
    United States

    Site Not Available

  • Investigator site 106

    Houston 4699066, Texas 4736286 77008
    United States

    Site Not Available

  • Investigator site 111

    McAllen 4709796, Texas 4736286 78501
    United States

    Site Not Available

  • Investigator site 105

    San Antonio 4726206, Texas 4736286 62269
    United States

    Site Not Available

  • Investigator site 101

    Salt Lake City, Utah 84107
    United States

    Site Not Available

  • Investigator site 101

    Salt Lake City 5780993, Utah 5549030 84107
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.